Jefferies Financial Group Initiates Coverage on Amgen (NASDAQ:AMGN)

Analysts at Jefferies Financial Group assumed coverage on shares of Amgen (NASDAQ:AMGN) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The firm set a “hold” rating and a $350.00 price target on the medical research company’s stock. Jefferies Financial Group’s price target would indicate a potential downside of 7.32% from the stock’s current price.

AMGN has been the subject of a number of other research reports. Daiwa Securities Group upped their price objective on shares of Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Argus upped their price target on Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a report on Friday, February 6th. Piper Sandler raised their price objective on Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Finally, Rothschild & Co Redburn lifted their price objective on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Amgen has a consensus rating of “Hold” and a consensus target price of $354.00.

Amgen Stock Up 0.6%

AMGN opened at $377.64 on Tuesday. The business has a 50 day moving average price of $356.15 and a 200 day moving average price of $324.33. Amgen has a twelve month low of $261.43 and a twelve month high of $391.29. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The firm has a market cap of $203.57 billion, a P/E ratio of 26.54, a price-to-earnings-growth ratio of 3.72 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter last year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts forecast that Amgen will post 20.62 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Anfield Capital Management LLC raised its stake in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the last quarter. Dogwood Wealth Management LLC boosted its stake in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares during the last quarter. Board of the Pension Protection Fund acquired a new stake in Amgen during the 4th quarter worth $26,000. Evelyn Partners Investment Management LLP bought a new stake in shares of Amgen during the 2nd quarter valued at $32,000. Finally, Howard Hughes Medical Institute acquired a new position in shares of Amgen in the 2nd quarter valued at $32,000. Institutional investors own 76.50% of the company’s stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Prominent market commentator Josh Brown argued that large-cap biotech names are resilient to disruption, which supports investor appetite for Amgen as a stable growth biotech. Josh Brown: Biotech growth stocks immune to disruption risk
• Positive Sentiment: Analysis highlighting Amgen’s oncology advances and a resilient dividend argues the company’s product progress and cash generation underpin long‑term growth, a supportive signal for income and growth investors. Amgen Oncology Advances Test Dividend Strength And Long Term Growth Story
• Neutral Sentiment: Seeking Alpha published the transcript of Amgen’s presentation at the Leerink Global Healthcare Conference — useful for pipeline, management commentary and strategic color, but no single market-moving announcement in the transcript. Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: A valuation piece assesses whether AMGN shares are mispriced after mixed returns — useful background for longer‑term positioning but not an immediate catalyst. Assessing Whether Amgen (AMGN) Shares Look Mispriced After Recent Mixed Returns
• Neutral Sentiment: Short‑interest reports in the feed show anomalous/zero values and contradictory entries for March — current data appears unreliable and is not a usable signal for positioning right now.
• Negative Sentiment: Jefferies initiated coverage on Amgen with a Hold and set a $350 price target, below the current market price — this analyst call introduces near‑term downside pressure and may weigh on sentiment. Jefferies initiates coverage of Amgen (AMGN) with hold recommendation
• Negative Sentiment: New federal legislation (H.R. 7871) that would formalize value‑based purchasing in Medicaid and change price/rebate calculations could create pricing/reporting pressures for manufacturers, introducing regulatory risk for Amgen’s marketed drugs. New Bill: Representative Brett Guthrie introduces H.R. 7871: Medicaid VBPs for Patients Act

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.